Company News-宜明昂科英文

2026-03-04

ImmuneOnco’s IMM0306S Subcutaneous Formulation for SLE Approved by NMPA; Autoimmune Pipeline Expands

This milestone marks a significant breakthrough in ImmuneOnco’s innovative drug development within the autoimmune disease sector.

2026-02-12

ImmuneOnco Announces NMPA Approval of Clinical Trial Application for Amulirafusp Alfa (IMM0306) in the Treatment of IgG4-Related Disease

This marks the world's first regulatory approval to initiate clinical trials of a CD47×CD20 bispecific agent in IgG4-RD, expanding IMM0306 into this challenging autoimmune indication and offering a differentiated dual-target therapeutic approach for patients with substantial unmet medical needs.

2026-01-28

ImmuneCare, a Subsidiary of ImmuneOnco, Files Patent for IMC-015 Bispecific Antibody Differentiated "Fat-Loss & Muscle-Gain" Strategy Poised to Tackle GLP-1-Induced Muscle Loss

Shanghai, China, 28 January 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,

2026-01-21

ImmuneOnco Presents at J.P. Morgan Healthcare Conference: Biotech Showcase™ Presentation Highlights Progress of Core Programs Including IMM01

Recently, a three-person delegation from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", Hong Kong Stock Exchange code: 01541.HK) attended the 44th J.P. Morgan Healthcare Conference. Dr.

2026-01-19

ImmuneCare, a Subsidiary of ImmuneOnco, Successfully Completes Subject Enrollment for First Cohort in MAD Study of IMC-003 for Pulmonary Arterial Hypertension

Shanghai, China, January 19, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,